Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.39 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.39 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.39 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.38 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3479578 | 1.00 | BACE1 (0.48) | BACE1SIGMAR1ALDH1A1POLBKMT2A | |
| SCHEMBL2818280 | 0.81 | BACE1 (0.48) | BACE1SIGMAR1ALDH1A1POLBKMT2A | |
| SCHEMBL2818282 | 0.81 | BACE1 (0.48) | BACE1SIGMAR1ALDH1A1POLBKMT2A | |
| SCHEMBL2818279 | 0.81 | BACE1 (0.48) | BACE1SIGMAR1ALDH1A1POLBKMT2A | |
| SCHEMBL3479607 | 0.81 | BACE1 (0.48) | BACE1SIGMAR1ALDH1A1POLBKMT2A | |
| SCHEMBL8206701 | 0.81 | NPFFR1 (0.54) | SIGMAR1ALDH1A1POLBKMT2ANPFFR1 | |
| SCHEMBL2434192 | 0.80 | PDK1 (0.42) | ALDH1A1POLBKMT2AKCNJ6KCNJ5 | |
| SCHEMBL12293409 | 0.73 | BACE1 (0.52) | BACE1KMT2A | |
| SCHEMBL4074761 | 0.73 | BACE1 (0.46) | BACE1SIGMAR1ALDH1A1POLBKMT2A | |
| SCHEMBL16494609 | 0.72 | ALDH1A1 (0.39) | ALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | BACE1, APP, PSEN1 | BACE1 1/4885SIGMAR1 4304/4885ALDH1A1 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.